p53 in breast cancer: mutation and countermeasures

被引:18
作者
Kumar, Sumit
Walia, Vijay
Ray, Maria
Elble, Randolph C.
机构
[1] So Illinois Univ, Sch Med, Dept Pharmacol, Springfield, IL 62794 USA
[2] So Illinois Univ, Sch Med, Inst Canc, Springfield, IL 62794 USA
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2007年 / 12卷
关键词
p53; breast cancer; mutation; MDM2; nutlin; therapy; review;
D O I
10.2741/2378
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
p53 is the primary arbiter of the mammalian cell's response to stress, the governor of life and death. It is the nexus upon which signals converge from an array of sensors that detect damage to DNA or to the mitotic spindle or the cytoskeleton, hypoxia, cell detachment, growth factor deprivation, oncogene expression and other forms of stress. Depending on the type, intensity and duration of the signals, p53 in turn transactivates batteries of genes specifying cell cycle arrest, DNA repair, apoptosis, or other anti- neoplastic functions. At the same time, p53 represses anti- apoptotic and survival functions. The type, intensity and duration of signaling dictate the sequellae. While this response is combinatorial, the frequent perturbation of p53 function in a wide spectrum of cancers attests to its central role in the suppression of neoplasia. As our understanding of regulation by and of p53 has deepened, many possibilities have been suggested for re- establishing p53 or its effectors in tumor cells. This review will briefly summarize the role of p53 mutations in the etiology and treatment of breast cancer and then consider the wide array of strategies being developed to re- establish p53 function in tumor cells.
引用
收藏
页码:4168 / 4178
页数:11
相关论文
共 129 条
[1]   Prognostic relevance of gene amplifications and coamplifications in breast cancer [J].
Al-Kuraya, K ;
Schraml, P ;
Torhorst, J ;
Tapia, C ;
Zaharieva, B ;
Novotny, H ;
Spichtin, H ;
Maurer, R ;
Mirlacher, M ;
Köchli, O ;
Zuber, M ;
Dieterich, H ;
Mross, F ;
Wilber, K ;
Simon, R ;
Sauter, G .
CANCER RESEARCH, 2004, 64 (23) :8534-8540
[2]   Structure and function in the p53 family [J].
Arrowsmith, CH .
CELL DEATH AND DIFFERENTIATION, 1999, 6 (12) :1169-1173
[3]   Current strategies and future directions for eluding adenoviral vector immunity [J].
Bangari, Dinesh S. ;
Mittal, Suresh K. .
CURRENT GENE THERAPY, 2006, 6 (02) :215-226
[4]   Enhanced phosphorylation of p53 by ATN in response to DNA damage [J].
Banin, S ;
Moyal, L ;
Shieh, SY ;
Taya, Y ;
Anderson, CW ;
Chessa, L ;
Smorodinsky, NI ;
Prives, C ;
Reiss, Y ;
Shiloh, Y ;
Ziv, Y .
SCIENCE, 1998, 281 (5383) :1674-1677
[5]   ADENOVIRUS PROTEINS FROM BOTH E1B READING FRAMES ARE REQUIRED FOR TRANSFORMATION OF RODENT CELLS BY VIRAL-INFECTION AND DNA TRANSFECTION [J].
BARKER, DD ;
BERK, AJ .
VIROLOGY, 1987, 156 (01) :107-121
[6]   An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].
Bischoff, JR ;
Kim, DH ;
Williams, A ;
Heise, C ;
Horn, S ;
Muna, M ;
Ng, L ;
Nye, JA ;
SampsonJohannes, A ;
Fattaey, A ;
McCormick, F .
SCIENCE, 1996, 274 (5286) :373-376
[7]   Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors [J].
Blagosklonny, MV ;
Trostel, S ;
Kayastha, G ;
Demidenko, ZN ;
Vassilev, LT ;
Romanova, LY ;
Bates, S ;
Fojo, T .
CANCER RESEARCH, 2005, 65 (16) :7386-7392
[8]   TP53 and breast cancer [J].
Borresen-Dale, AL .
HUMAN MUTATION, 2003, 21 (03) :292-300
[9]   Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation [J].
Brooks, CL ;
Gu, W .
CURRENT OPINION IN CELL BIOLOGY, 2003, 15 (02) :164-171
[10]   Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs [J].
Bykov, VJN ;
Issaeva, N ;
Zache, N ;
Shilov, A ;
Hultcrantz, M ;
Bergman, J ;
Selivanova, G ;
Wiman, KG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (34) :30384-30391